Jones Lang LaSalle examines global Life Sciences clusters, and explores the advantages and strategic strengths of both emerging and established clusters and how they can effect a company's growth and health.
From the report:
"Established clusters within the United States and Europe remain destinations of choice for core aspects of drug discovery. Companies are able to offset the high costs of operating in established clusters with the increased odds of innovation due to deep, rich talent pools and infrastructure. Emerging global clusters, however, offer cost-advantageous manufacturing sites that provide both revenue and margin opportunities. Additionally, emerging clusters are becoming more competitive in hightech aspects of the value chain, due to significant capital investments and improved political policies."
Please note: This 97-page report may take a few moments to load.
There are no comments
Please login to post comments